Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
Biogen today announced positive, top-line data from the pivotal cohort (Part B) of the Phase II/III DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). 4 September 2024
Pharmaceutical
New Phase II data from Roche (ROG: SIX) show its BTK inhibitor, fenebrutinib, demonstrated near-complete suppression of disease activity and disability progression in relapsing multiple sclerosis (MS). 4 September 2024
Pharmaceutical
Recursion (Nasdaq: RXRX) has seen its shares fall by more than 15% following the announcement of Phase II trial results for REC-994, an investigational treatment for symptomatic cerebral cavernous malformation (CCM). 4 September 2024
Biotechnology
A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics, a muscle disease company developing therapeutics for people living with genetically-driven diseases. 3 September 2024
Biotechnology
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) continues to evolve with the introduction of new therapies. 3 September 2024
Pharmaceutical
California, USA-based vaccine developer Vaxcyte saw its shares leap almost 33% to $107.12 in pre-market activity as it revealed very impressive early-stage trial results. 3 September 2024
Pharmaceutical
Novo Nordisk’s semaglutide—marketed under the names Wegovy and Ozempic—have already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too. 2 September 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals has unveiled highly anticipated pancreatitis results from a late-stage trial of plozasiran, several months after reporting top-line data. 2 September 2024
Pharmaceutical
Sanofi (Euronext: SAN) has announced results from the HERCULES Phase III study, with BTK blocker tolebrutinib meeting the primary efficacy endpoint in non-relapsing secondary progressive multiple sclerosis (nrSPMS). 2 September 2024
Biotechnology
Johnson & Johnson said yesterday that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking the first approval of nipocalimab. 30 August 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze